

Applicants : BERMUDES, et al.  
U.S. Serial No.: 10/790,586  
Filed : March 1, 2004  
Page : 4

Amendments to the claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1 - 43 (Canceled)

44. (Currently Amended) An attenuated *Salmonella* sp. which expresses an F' pilus and contains produces a filamentous bacteriophage, whereby said *Salmonella* sp. *Salmonella* strain is a *msbB* mutant and said bacteriophage expresses a proteinaceous molecule under the control of a eukaryotic promotor non-pyrogenic and tumor-targeting.
45. (Canceled)
46. (Currently Amended) The *Salmonella* sp. of claim 44 45, wherein the *Salmonella* sp. *enteritidis* is *Salmonella typhimurium*.
47. (Currently Amended) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. is further attenuated by a mutation selected from the group consisting of a lipid mutation, a pur<sup>-</sup> mutation, and a combination thereof.
48. (Canceled)
49. (Currently Amended) The *Salmonella* sp. of claim 46, wherein the *Salmonella typhimurium* is derived from the strain selected from the group consisting of YS72 (ATCC Accession

Applicants : BERMUDES, et al.  
U.S. Serial No.: 10/790,586  
Filed : March 1, 2004  
Page : 5

No. 55680), XS1456 (ATCC Accession No. 202164), and YS1646 (ATCC Accession No. 202165).

50. (Canceled)

51. (Canceled)

52. (Currently Amended) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. delivers at least 1.7  $2.7 \times 10^9$  p.f.u. (plaque forming unit) of bacteriophage/gram of tumor.

53. (Currently Amended) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. delivers about 5.9  $17 \times 10^9$  p.f.u. (plaque forming unit) of bacteriophage/gram of tumor.

54. (Canceled)

55. (Currently Amended) The *Salmonella* sp. of claim 54 44, wherein the proteinaceous molecule is selected from the group consisting of green fluorescent protein (GFP), IL-2/pIII fusion protein, and listericolysin O (LLO) 91-99.

56. (Canceled)

57. (Currently Amended) The *Salmonella* sp. of claim 56 44, wherein the eukaryotic promoter is a cytomegalovirus (CMV) promoter.

58. (Original) The *Salmonella* sp. of claim 44, wherein the *Salmonella* sp. is lac<sup>r</sup> and kanamycin-resistant.

Applicants : BERMUDES, et al.  
U.S. Serial No.: 10/790,586  
Filed : March 1, 2004  
Page : 6

59. (Canceled)

60. (Original) A composition comprising the *Salmonella* sp. of claim 44 and a pharmaceutically-acceptable carrier.

61. (Currently Amended) A method of delivering a bacteriophage to a solid tumor, comprising the intravenous administration of an attenuated ~~tumor-targeting~~ *Salmonella* sp. which expresses an F' pilus and contains produces a filamentous bacteriophage, whereby said *Salmonella* sp. *Salmonella* strain is a msbB<sup>-</sup> mutant and said bacteriophage expresses a proteinaceous molecule under the control of a eukaryotic promoter non-pyrogenic and ~~tumor targeting~~.

62. (Currently Amended) A kit comprising an attenuated *Salmonella* sp. which expresses an F' pilus and contains produces a filamentous bacteriophage, whereby said *Salmonella* sp. *Salmonella* strain is a msbB<sup>-</sup> mutant and said bacteriophage expresses a proteinaceous molecule under the control of a eukaryotic promoter non-pyrogenic and ~~tumor targeting~~.